Delhi, July 09, 2025 (GLOBE NEWSWIRE) — US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights:
- US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030
- Insight On FDA Designated Orphan Drugs In Clinical Trials: > 850 Orphan Drugs
- Clinical Trials Insight By Company, Indication, Phase and Priority Status
- Insight On FDA Designated Marketed Orphan Drugs: > 500 Orphan Drugs
- Pricing and Dosage Insight: > 400 Marketed Orphan Drugs
- US, Global, Regional, Annual Sales Insight (2019 – Q1’2025): >150 Orphan Drugs
- Sales, Price and Dosage Data Represented In More Than 1000 Charts and Tables
- Orphan Designation Insight By Indication, Company, Trial Phase, Marketed Drugs Represented In 1000 Tables
Download Report: https://www.kuickresearch.com/report-fda-orphan-drug-database
The U.S. orphan drug market remains one of the most promising and rapidly evolving segments within the pharmaceutical industry, reflecting significant growth driven by favourable regulatory policies, ongoing clinical research advancements, and robust market dynamics. Increasingly, pharmaceutical companies are shifting their strategic focus toward rare diseases, incentivized by the FDA’s Orphan Drug Act, which provides key regulatory benefits such as market exclusivity, tax …